In vivo efficacy of meglumine antimoniate-loaded nanoparticles for cutaneous leishmaniasis : a systematic review
Background: Nanotechnology is a promising strategy to improve existing antileishmanial agents. Objective: To explore the evidence of encapsulated meglumine antimoniate for cutaneous leishmaniasis treatment in animal models. Materials & methods: The studies were recovered from PubMed, Scopus, EMBASE, LILACS, WoS and Google according to eligibility criteria following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) and the Population, Intervention, Comparison, Outcomes and Study design (PICOS) strategy. Study appraisal was assessed using the Animal Research Reporting of In Vivo Experiments, SYstematic Review Centre for Laboratory animal Experimentation (SYRCLE) and Grading of Recommendations Assessment, Development and Evaluation (GRADE) recommendations. Results: Five studies were included. Liposomes, metallic and polymeric nanoparticles were tested in BALB/c mice against Leishmania major, L. tropica or L. amazonensis. Limitations: Few studies were found to meet the eligibility criteria. Conclusion: All formulations had a significant efficacy, similar to the meglumine antimoniate reference treatment concerning the lesion size and parasite burden. The studies had a high and moderate risk of bias, and the confidence in cumulative evidence was considered low. Therefore, we encourage the development of high-quality preclinical studies. Registration: PROSPERO register CRD42020170191.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:16 |
|---|---|
| Enthalten in: |
Nanomedicine (London, England) - 16(2021), 17 vom: 01. Juli, Seite 1505-1518 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Pereira, Meliana Borilli [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 04.08.2021 Date Revised 04.08.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.2217/nnm-2021-0119 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM327368292 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM327368292 | ||
| 003 | DE-627 | ||
| 005 | 20231225200631.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2217/nnm-2021-0119 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1091.xml |
| 035 | |a (DE-627)NLM327368292 | ||
| 035 | |a (NLM)34189952 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Pereira, Meliana Borilli |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a In vivo efficacy of meglumine antimoniate-loaded nanoparticles for cutaneous leishmaniasis |b a systematic review |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.08.2021 | ||
| 500 | |a Date Revised 04.08.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Background: Nanotechnology is a promising strategy to improve existing antileishmanial agents. Objective: To explore the evidence of encapsulated meglumine antimoniate for cutaneous leishmaniasis treatment in animal models. Materials & methods: The studies were recovered from PubMed, Scopus, EMBASE, LILACS, WoS and Google according to eligibility criteria following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) and the Population, Intervention, Comparison, Outcomes and Study design (PICOS) strategy. Study appraisal was assessed using the Animal Research Reporting of In Vivo Experiments, SYstematic Review Centre for Laboratory animal Experimentation (SYRCLE) and Grading of Recommendations Assessment, Development and Evaluation (GRADE) recommendations. Results: Five studies were included. Liposomes, metallic and polymeric nanoparticles were tested in BALB/c mice against Leishmania major, L. tropica or L. amazonensis. Limitations: Few studies were found to meet the eligibility criteria. Conclusion: All formulations had a significant efficacy, similar to the meglumine antimoniate reference treatment concerning the lesion size and parasite burden. The studies had a high and moderate risk of bias, and the confidence in cumulative evidence was considered low. Therefore, we encourage the development of high-quality preclinical studies. Registration: PROSPERO register CRD42020170191 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Systematic Review | |
| 650 | 4 | |a Leishmania | |
| 650 | 4 | |a cutaneous leishmaniasis | |
| 650 | 4 | |a meglumine antimoniate | |
| 650 | 4 | |a nanoparticles | |
| 650 | 4 | |a nanotechnology | |
| 650 | 7 | |a Antiprotozoal Agents |2 NLM | |
| 650 | 7 | |a Meglumine Antimoniate |2 NLM | |
| 650 | 7 | |a 75G4TW236W |2 NLM | |
| 700 | 1 | |a Sydor, Bruna Gomes |e verfasserin |4 aut | |
| 700 | 1 | |a Memare, Karla Gabriela |e verfasserin |4 aut | |
| 700 | 1 | |a Verzignassi Silveira, Thaís Gomes |e verfasserin |4 aut | |
| 700 | 1 | |a Alessi Aristides, Sandra Mara |e verfasserin |4 aut | |
| 700 | 1 | |a Dalmarco, Eduardo Monguilhott |e verfasserin |4 aut | |
| 700 | 1 | |a Vieira Teixeira, Jorge Juarez |e verfasserin |4 aut | |
| 700 | 1 | |a Campana Lonardoni, Maria Valdrinez |e verfasserin |4 aut | |
| 700 | 1 | |a Demarchi, Izabel Galhardo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nanomedicine (London, England) |d 2006 |g 16(2021), 17 vom: 01. Juli, Seite 1505-1518 |w (DE-627)NLM17228452X |x 1748-6963 |7 nnns |
| 773 | 1 | 8 | |g volume:16 |g year:2021 |g number:17 |g day:01 |g month:07 |g pages:1505-1518 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2217/nnm-2021-0119 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 16 |j 2021 |e 17 |b 01 |c 07 |h 1505-1518 | ||